| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Spyre Therapeutics, Inc. (SYRE) has 10 insiders with recent SEC Form 4 filings, including 24 buys and 2 sells. SYRE is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 597.5K | $52.79M | -15,000 | |
| Other | 313.3K | $27.68M | -8,333 | |
| Other | 140.0K | $12.37M | - | |
| CFO | 103.7K | $9.16M | -7,500 | |
| Dir | 8.0K | $709.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 17, 2019 | Quinn Anthony G. | President &CEO | Buy | 18,713 | $6.75 | $126,398.71 | +1.7% | |
| Sep 27, 2018 | Schuchart Aaron | Chief Business Officer | Sell | 6,000 | $9.50 | $57,005.00 | -35.5% | |
| Aug 15, 2018 | Quinn Anthony G. | President &CEO | Buy | 2,994 | $7.05 | $21,115.22 | +1.6% | |
| Dec 8, 2017 | Quinn Anthony G. | Interim CEO | Buy | 8,288 | $4.96 | $41,078.38 | +8.8% | |
| Dec 5, 2017 | York Charles N II76 | Chief Financial Officer And VP | Buy | 25,959 | $4.48 | $116,222.95 | +27.9% | |
| Dec 5, 2017 | Quinn Anthony G. | Director | Buy | 17,121 | $4.86 | $83,177.50 | +37.1% | |
| Feb 21, 2017 | Orbimed Advisors LLC67 | 10% Owner | Buy | 109,300 | $5.16 | $563,882.00 | +2.6% | |
| Apr 12, 2016 | Lilly Eli & Co | 10% Owner | Buy | 500,000 | $10.00 | $5,000,000.00 | +24.2% | |
| Apr 12, 2016 | Cox Russell J. | Director | Buy | 7,000 | $10.00 | $70,000.00 | New | |
| Apr 12, 2016 | Quinn Anthony | Director | Buy | 10,000 | $10.00 | $100,000.00 | New |